daratumumab (Darzalex®)

Reference No. 2834

Publication date:

30/09/2016

Appraisal information

daratumumab (Darzalex®) 20 mg/ml concentrate for solution for infusion

Company:	Janssen-Cilag Ltd
BNF category:	Malignant disease and immunosupression
NMG meeting date:	Not scheduled
AWMSG meeting date:	Not scheduled

Submission Type:	Nonsubmission
Status:	Superseded
Advice No:	Not available
Ratification by Welsh Government:	29/09/2016

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA510) ISSUED JANUARY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Statement of Advice (SOA)

Download

daratumumab (Darzalex) 2834 SOA